Reinhard Dummer

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1)
    R Dummer
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Leuk Lymphoma 28:515-22. 1998
  2. ncbi Immunomodulators in the treatment of cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Expert Opin Biol Ther 2:279-86. 2002
  3. ncbi Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides?
    Reinhard Dummer
    Department of Dermatology, University Hospital, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Arch Dermatol 138:199-203. 2002
  4. ncbi Cutaneous T-cell lymphomas: prognosis and quality-of-life issues
    R Dummer
    Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland
    Clin Lymphoma 1:S21-5. 2000
  5. ncbi GVAX (Cell Genesys)
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Curr Opin Investig Drugs 2:844-8. 2001
  6. ncbi Swiss guidelines for the treatment and follow-up of cutaneous melanoma
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Dermatology 203:75-80. 2001
  7. ncbi [Current pathogenetic aspects of Sézary syndrome and mycosis fungoides]
    R Dummer
    Universitatsspital Zurich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zurich, Schweiz
    Hautarzt 52:189-92. 2001
  8. ncbi Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication
    R Dummer
    Department of Dermatology, University Hospital Zurich, and the Department of Virology, University of Zurich, Switzerland
    Blood 97:523-7. 2001
  9. ncbi [Immuno-intervention in cutaneous lymphomas]
    R Dummer
    Dermatologische Klinik, Universitatsspital Zurich
    Praxis (Bern 1994) 89:1471-6. 2000
  10. ncbi Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Cancer Gene Ther 7:1069-76. 2000

Detail Information

Publications119 found, 100 shown here

  1. ncbi Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1)
    R Dummer
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Leuk Lymphoma 28:515-22. 1998
    ..These results imply perspectives for new therapeutical approaches, such as IL-12 or chimeric fusion proteins...
  2. ncbi Immunomodulators in the treatment of cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Expert Opin Biol Ther 2:279-86. 2002
    ..New treatment approaches include fusion toxins and chimeric monoclonal antibodies (mAbs) such as rituximab for CBCLs. The identification of tumour antigens in CTCLs renders these diseases susceptible for vaccination approaches...
  3. ncbi Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides?
    Reinhard Dummer
    Department of Dermatology, University Hospital, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Arch Dermatol 138:199-203. 2002
    ..To evaluate the clinical and prognostic features in primary cutaneous CD8+ T-cell lymphomas, which are rare and considered to be aggressive cutaneous lymphoproliferative disorders...
  4. ncbi Cutaneous T-cell lymphomas: prognosis and quality-of-life issues
    R Dummer
    Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland
    Clin Lymphoma 1:S21-5. 2000
    ..Due to the anatomical localization, these lymphomas have significant impact on the quality of life of the patient...
  5. ncbi GVAX (Cell Genesys)
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Curr Opin Investig Drugs 2:844-8. 2001
    ..The high-potency form of GVAX is similar to the first-generation product except that it releases an increased quantity of immune system stimulant [405932]...
  6. ncbi Swiss guidelines for the treatment and follow-up of cutaneous melanoma
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Dermatology 203:75-80. 2001
    ..They have been approved by all Swiss medical societies involved in the care of melanoma patients...
  7. ncbi [Current pathogenetic aspects of Sézary syndrome and mycosis fungoides]
    R Dummer
    Universitatsspital Zurich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zurich, Schweiz
    Hautarzt 52:189-92. 2001
    ..This interferon resistance may be an Achilles heel that can be targeted by molecular therapeutic interventions...
  8. ncbi Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication
    R Dummer
    Department of Dermatology, University Hospital Zurich, and the Department of Virology, University of Zurich, Switzerland
    Blood 97:523-7. 2001
    ..Furthermore, this approach may allow specific molecular interventions, resulting in the efficient treatment of CTCL and other IFN-resistant neoplasms such as lung cancer...
  9. ncbi [Immuno-intervention in cutaneous lymphomas]
    R Dummer
    Dermatologische Klinik, Universitatsspital Zurich
    Praxis (Bern 1994) 89:1471-6. 2000
    ....
  10. ncbi Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Cancer Gene Ther 7:1069-76. 2000
    ..t. injection of a replication-defective adenoviral expression vector is safe, feasible, and biologically effective (with respect to transduction frequency) in patients with either metastatic melanoma or breast cancer...
  11. ncbi Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 10:4959-70. 2004
    ..Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha...
  12. ncbi Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Natl Cancer Inst 97:1143-53. 2005
    ..We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro...
  13. ncbi Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells
    Lucie Heinzerling
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 106:2287-94. 2005
    ..All patients demonstrated an increased antimeasles antibody titer after therapy. The data demonstrate that CTCLs are promising targets for an MV-based oncolytic therapy...
  14. ncbi [Perspective of cutaneous lymphoma reserach]
    Reinhard Dummer
    Dermatologische Klinik, Universitatsspital Zurich, Schweiz
    J Dtsch Dermatol Ges 4:492-5. 2006
    ..The new WHO/EORTC classification definitely will facilitate a more detailed investigation of the various subtypes...
  15. ncbi Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy
    Lucie Heinzerling
    Department of Dermatology, University of Zurich, CH 8091 Zurich, Switzerland
    Hum Gene Ther 16:35-48. 2005
    ..Serum levels revealed fluctuations. The results show that intratumoral injection of DNA produced some beneficial clinical effect. DNA encoding a cytokine may be useful as a therapeutic or adjuvant against various human cancers...
  16. doi Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
    Simone M Goldinger
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland Electronic address
    Eur J Cancer 50:406-10. 2014
    ..This clinical investigation encourages further studies in prospective clinical trials to define the optimal treatment schedule for the MAPK pathway inhibition and should be accompanied by molecular monitoring using repeated biopsies...
  17. doi Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching
    Daniel S Widmer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Invest Dermatol 133:2436-43. 2013
    ..Thus, exposure of proliferative melanoma cells to hypoxic microenvironments is sufficient, in a HIF1α-dependent manner, to downregulate melanocytic marker expression and increase their invasive potential. ..
  18. doi Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistr 100, 8091, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 35:1786-95. 2008
    ..This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients...
  19. ncbi S-100B and FDG-PET/CT in therapy response assessment of melanoma patients
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 215:192-201. 2007
    ..To compare the value of the tumor marker S-100B protein and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in patients treated for melanoma metastases...
  20. doi Aldara activates TLR7-independent immune defence
    Anne Walter
    Department of Oncology, University Hospital Zurich, Wagistrasse 14, 8952 Schlieren, Switzerland
    Nat Commun 4:1560. 2013
    ..Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara...
  21. ncbi CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland
    Hum Pathol 36:1020-4. 2005
    ..MxA protein, representing the surrogate marker for lesional type I interferon activity, was expressed in 4 of 5 evaluated cases. Our findings further substantiate the putative pDC origin of CD4+CD56+ HNs...
  22. doi Melanoma after laser therapy of pigmented lesions--circumstances and outcome
    Marie C Zipser
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Eur J Dermatol 20:334-8. 2010
    ..A careful examination of all pigmented lesions using surface microscopy and representative biopsies in combination with a close follow-up is recommended...
  23. doi Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Mol Ther 16:985-94. 2008
    ..Our results show that intratumoral injections of TG1024 are safe and well tolerated. The clinical activity of TG1024 observed in this study warrants further investigations...
  24. doi Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3
    Laurence Feldmeyer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Electronic address
    J Am Acad Dermatol 69:530-6. 2013
    ..Ultraviolet (UV) B radiation increases serum 25-hydroxyvitamin-D3 [25(OH)D], but the influence of UVA1 and UVA/narrowband UVB (UVBnb) phototherapy on serum vitamin D is unknown...
  25. ncbi Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients
    Karin Murer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Melanoma Res 14:257-62. 2004
    ..0038). This could not be shown for any of the markers tested by FACS. Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival...
  26. doi Systematic classification of melanoma cells by phenotype-specific gene expression mapping
    Daniel S Widmer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 25:343-53. 2012
    ..These findings reinforce the concept that a two-state system, as described by the phenotype switching model, underlies melanoma progression...
  27. pmc The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report
    Ossia M Eichhoff
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Melanoma Res 20:349-55. 2010
    ..These results highlight the likelihood that disease progression involves melanoma cells retaining the capacity to regulate the expression of metastatic potential critical factors according to changing microenvironmental conditions...
  28. ncbi Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Arch Dermatol 139:1325-32. 2003
    ..It enhances innate and acquired immune responses via endogenous cytokine production and has proven efficacious in clearing superficial basal cell carcinoma (sBCC)...
  29. pmc Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients
    Alessandra Curioni-Fontecedro
    Division of Internal Medicine and Clinic of Oncology, University Hospital, Zurich, Switzerland
    PLoS ONE 6:e21418. 2011
    ..01). Our results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a potent predictor of sentinel lymph node metastasis...
  30. ncbi Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Electronic address
    Eur J Cancer 50:611-21. 2014
    ..Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases...
  31. pmc RASopathic skin eruptions during vemurafenib therapy
    Jeannine D Rinderknecht
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    PLoS ONE 8:e58721. 2013
    ..Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions...
  32. ncbi Expression of melanoma-associated antigens in melanoma cell cultures
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:491-7. 2005
    ..05-0.001). Elucidation of the MAA expression patterns and the kinetics within the same patient as well as during the course of the disease may help improve current and develop new immunotherapeutic strategies...
  33. doi Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas
    Anne Walter
    Laboratory of Tumor Immunology, Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 16:3562-70. 2010
    ..To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC...
  34. ncbi Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma
    Antonio Cozzio
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Leuk Lymphoma 47:865-9. 2006
    ..All other patients remained free of disease. Thus, intra-lesional IFNalpha2a may represent a valuable alternative to surgery and radiotherapy as first-line treatment of pcMZL...
  35. doi Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Melanoma Res 18:104-11. 2008
    ..Local GM-CSF expression could be induced. In summary, ALVAC GM-CSF and ALVAC IL-2 injections are safe and can mediate local biologic and immunologic effects...
  36. ncbi Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 103:1796-8. 2004
    ..Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance, thus contributing to aggressive phenotype of these lymphoma entities...
  37. doi Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate
    Beda Mühleisen
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Histopathology 55:67-76. 2009
    ..The aim was to determine whether qualitative and quantitative differences in perineoplastic inflammation in OTRs contribute to the increased carcinogenesis...
  38. ncbi Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 121:1764-70. 2007
    ..005). This suggests that BMI-1 mediated repression of p16(ink4a) may contribute to an increased aggressive behavior of stem cell-like melanoma cells...
  39. ncbi Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression
    Chunlei Zhang
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Hum Pathol 38:995-1002. 2007
    ..Thus, cutaneous T-cell lymphoma cells show changes in oncogene and tumor suppressor gene expression that increase proliferation...
  40. pmc Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients
    Natko Nuber
    Department of Oncology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 107:15187-92. 2010
    ..This study shows that CT7 can induce specific cellular immunity in melanoma patients. Based on these findings, CT7 will be further explored as a potential vaccine for melanoma immunotherapy...
  41. ncbi Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand
    Jörg Willers
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 9:2744-54. 2003
    ..Proliferation and apoptosis of cultured cells were measured by 5-bromo-2-desoxyuridine and propidium iodine incorporation...
  42. doi Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
    Benedetta Belloni
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Clin Pathol 66:124-35. 2013
    ..However, molecular analysis is impaired by the cross linking properties of formalin. The PAXgene tissue system (PreAnalytix, Switzerland) is a new formalin-free tissue collection device...
  43. pmc Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
    ..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...
  44. doi Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth
    Gianluca Civenni
    Institute of Anatomy and Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
    Cancer Res 71:3098-109. 2011
    ....
  45. ncbi Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 34:1366-75. 2007
    ..To evaluate the usefulness of PET/CT in melanoma patients with an elevated serum S-100B tumour marker level...
  46. ncbi Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells
    Chun Lei Zhang
    Department of Dermatology, University Hospital of Zurich, CH 8091 Zurich, Switzerland
    J Pathol 200:249-54. 2003
    ..Overexpression of Mcl-1 and synthesis of non-functional Bax may be responsible for the resistance of CTCL cells to the anti-cancer drugs chlorambucil and sulindac...
  47. pmc Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients
    Simone M Goldinger
    Dermatology and Pathology Departments, University Hospital of Zurich, Zurich, Switzerland
    Eur J Immunol 42:3049-61. 2012
    ..We conclude that the simultaneous use of both Imiquimod and CpG-ODN induced combined memory and effector CD8(+) T-cell responses...
  48. ncbi Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis
    Jörg Willers
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:543-50. 2005
    ..Moreover tyrosinase peptide antigens might be used as key tools in studying the boundaries between self-tolerance and autoimmunity phenomena...
  49. ncbi Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness
    Christian D Mnich
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Melanoma Res 17:131-6. 2007
    ..We hypothesize that the observed decrease in transforming growth factor beta signalling in thicker primary melanomas is due to the increased production of signalling inhibitors...
  50. pmc Tumor cell plasticity and angiogenesis in human melanomas
    Daniela Mihic-Probst
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 7:e33571. 2012
    ..0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation...
  51. doi Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography
    Patrick A Oberholzer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 217:351-5. 2008
    ..Baseline staging is important in all melanoma types, including melanoma with unknown primary site (MUP). Staging includes different examination strategies, each with different accuracy...
  52. ncbi Novel MITF targets identified using a two-step DNA microarray strategy
    Keith S Hoek
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 21:665-76. 2008
    ..Many of these new targets have known relevance to pigmentation and melanoma biology, and further emphasize the critical role of MITF in these processes...
  53. doi A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
    Marie C Zipser
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 24:326-33. 2011
    ..This suggests that while current therapeutic strategies target proliferative melanoma cells, future approaches should also account for the invasive phenotype population...
  54. doi Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching
    Ossia M Eichhoff
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 24:631-42. 2011
    ..Our data show that melanoma cell phenotype switching behaviour is regulated by differential LEF1/TCF4 activity...
  55. ncbi Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 211:318-24. 2005
    ..Apoptotic pathway aberrations are reported as important tumor progression factors in melanoma...
  56. ncbi High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistr 100, 8091 Zurich, Switzerland
    Radiology 244:566-74. 2007
    ....
  57. ncbi Weight of decision-making impairs clinical assessment of melanocytic lesions
    Tamara Gächter
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Cutan Med Surg 11:9-18. 2007
    ..We studied the weight of decision-making on clinical assessment of melanocytic lesions judging benign, atypical, and malignant lesions; common mistakes; and total removal rates, comparing dermatologists with nondermatologists...
  58. ncbi Recent advances in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    J Dermatol Sci 48:157-67. 2007
    ....
  59. doi Engineering melanoma progression in a humanized environment in vivo
    Gregor Kiowski
    Cell and Developmental Biology, Institute of Anatomy, University of Zurich, Zurich, Switzerland
    J Invest Dermatol 132:144-53. 2012
    ..Therefore, in one defined model system, tumor cell-autonomous and non-autonomous pathways regulating human disease progression can be investigated in a humanized, clinically relevant context...
  60. doi Cutaneous lymphomas: molecular pathways leading to new drugs
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Invest Dermatol 132:517-25. 2012
    ..The rational and well-coordinated application of these tools, together with improved chemotherapeutic options, will hopefully further improve treatment success in the near future...
  61. ncbi Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
    Maja Wuest
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich, Switzerland
    Arch Dermatol Res 299:493-8. 2007
    ..Via induction of Notch signaling imiquimod may exert tumor suppressor function, which together with its proinflammatory properties results in tumor regression...
  62. doi In vivo switching of human melanoma cells between proliferative and invasive states
    Keith S Hoek
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Cancer Res 68:650-6. 2008
    ..We present a new model for melanoma progression that accounts for transcription signature plasticity and provides a more rational context for explaining observed melanoma biology...
  63. pmc Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro
    Alessandra Curioni Fontecedro
    Faculty of Mathematics and Natural Sciences, Institute of Molecular Life Sciences, University of Zurich, and Department of Dermatology, University Hospital of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Virol J 7:175. 2010
    ..Most trans-complementing studies involved transgene expressions from strong ubiquitous promoters, and thereby relied entirely on the cancer cell specificity of the CRAd vector...
  64. pmc Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Mol Ther 18:1244-7. 2010
    ..CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy...
  65. ncbi Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells
    Natalie C Schlegel
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 22:445-53. 2009
    ..We conclude that transition to increased aggressiveness in melanoma cells requires Id2 upregulation to suppress TGF-beta induction of p15(Ink4b) and thus help to circumvent TGF-beta-mediated inhibition of proliferation...
  66. ncbi Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fun
    Philippa Golling
    Department of Dermatology, Cutaneous Lymphoma Study Group, University Hospital, Zurich, Switzerland
    Leuk Lymphoma 49:1094-103. 2008
    ..Surgical excision or radiotherapy is highly effective in pcMZL and pcFCL...
  67. ncbi Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein
    Mirjam Beyeler
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 213:187-91. 2006
    ..Early detection of melanoma recurrence is essential for the patient's prognosis. The serum S100 level may be a useful tool to detect relapse early...
  68. ncbi Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors
    Michel Gilliet
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Arch Dermatol 140:1490-5. 2004
    ..It has been proposed that the innate immune system plays a central role in driving the autoimmune T-cell cascade leading to psoriasis; however, there is no direct evidence for this...
  69. ncbi p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital, Zurich, Switzerland
    Int J Cancer 118:2262-8. 2006
    ..Therefore, immunohistochemical evaluation for p16 expression is of potential value for treatment planning in melanoma surgery...
  70. ncbi Extracutaneous transformation into a high-grade lymphoma: a potential pitfall in the management of patients with Sézary syndrome
    Sonja Michaelis
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Int J Dermatol 45:277-9. 2006
    ..Transformation into a high-grade lymphoma in cutaneous T-cell lymphoma (CTCL) occurs in approximately 25% of cases and is associated with an aggressive clinical course...
  71. ncbi Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2
    Beate Zagrodnik
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Cancer 98:2708-14. 2003
    ..In the current article, the authors report recurrence rates among patients with BCC after superficial radiotherapy as well as Bcl-2 and p53 expression levels stratified by BCC subtype...
  72. ncbi The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions
    Dmitry V Kazakov
    Unit of Dermatopathology, Department of Dermatology, University Hospital, Zurich, Switzerland
    Am J Dermatopathol 26:102-7. 2004
    ....
  73. ncbi Cutaneous malignant lymphomas: update 2006
    Gunter Burg
    Dept of Dermatology, University Hospital, Zurich, Switzerland
    J Dtsch Dermatol Ges 4:914-33. 2006
    ..Besides the classical options for therapy, there are new and "experimental" strategies, the efficacy of which has to be studied in clinical trials...
  74. doi Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls
    Christian D Mnich
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Exp Dermatol 18:69-77. 2009
    ..Topical GTE (OM24) reduces UVB-mediated epithelial damage already at low, cosmetically usable concentrations, without tachyphylaxis over 5 weeks, suggesting GTE as suitable everyday photochemopreventive agents...
  75. doi Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders
    Karin Schad
    University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
    Clin Cancer Res 16:1058-64. 2010
    ..AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies...
  76. ncbi Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer
    Andreas Trojan
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lung Cancer 44:143-7. 2004
    ..Our results indicate that CD8+ T cells infiltrating the tumor cell nests may be inadequately activated and thus incapable of mounting an effective anti-tumor immune response...
  77. ncbi Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC)
    Werner Kempf
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Arch Dermatol 144:1609-17. 2008
    ..We studied 19 patients with granulomatous CTCLs to further characterize the clinicopathological, therapeutic, and prognostic features...
  78. ncbi HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Blood 99:609-17. 2002
    ..001). HLA-G up-regulation together with IL-10 expression in CL might additionally contribute to the evasion of immunosurveillance and facilitate the transition from low- to high-grade lymphomas...
  79. ncbi WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects
    Gunter Burg
    Department of Dermatology, University Hospital Zurich, Switzerland
    J Cutan Pathol 32:647-74. 2005
    ..These findings always have to be interpreted in the context of the clinical features and biologic behavior...
  80. ncbi Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL)
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Semin Oncol 33:S33-6. 2006
    ..Other identified agents include vaccines and monoclonal antibodies. This article reviews some of the most recent clinical innovations...
  81. ncbi The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas
    Cornelia Schwab
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Br J Haematol 118:1019-26. 2002
    ..We conclude that identification and monitoring of CD4+Vbeta+ clonal T cells by fluorescence-activated cell sorting with double staining is a suitable method to assess clinical responses to different therapies...
  82. ncbi Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Semin Oncol 33:S26-32. 2006
    ..This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient...
  83. ncbi Role of imiquimod in skin cancer treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Dermatol 5:453-8. 2004
    ..This article reviews current literature on the use of imiquimod in the treatment of nonmelanoma and melanoma skin cancer...
  84. ncbi Mycosis fungoides--analysis of the duration of disease stages in patients who progress and the time point of high-grade transformation
    Jivko Kamarashev
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Int J Dermatol 46:930-5. 2007
    ..In order to better understand the dynamics of the disease and the prognostic implications in patients who progress, we studied the duration of each stage and the time at which blast transformation occurred...
  85. ncbi Cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University of Zurich, Switzerland
    J Dtsch Dermatol Ges 5:605-17. 2007
    ..Treatment is dependent on stage. As complete cure is not possible, it is essential to control the disease and alleviate symptoms. In recent years numerous new drugs have been developed to treat these diseases...
  86. ncbi Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Clin Oncol 24:1188-94. 2006
    ..This open-label, randomized study evaluated the safety, tolerability, and efficacy of subcutaneous PEG-IFNalpha-2a in patients with metastatic malignant melanoma (stage IV American Joint Committee on Cancer staging system)...
  87. doi [Current therapy of carcinoma of the skin]
    Reinhard Dummer
    Dermatologische Klinik, Universitatsspital Zurich, Gloriastrasse, Zurich
    Ther Umsch 67:447-52. 2010
    ..We recommend according international guidelines that these patients are treated in the context of clinical trials in a melanoma reference center...
  88. ncbi Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 207:116-8. 2003
    ..However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months...
  89. ncbi Exploring primary cutaneous B-cell lymphoma by microarray technology
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Invest Dermatol 120:vii-viii. 2003
  90. ncbi Cutaneous lymphomas and pseudolymphomas: newly described entities
    Dmitry V Kazakov
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Recent Results Cancer Res 160:283-93. 2002
    ..In the context of pseudolymphomas, cutaneous follicular lymphoid hyperplasia with monotypic plasma cells, pleomorphic reactions in molluscum contagiosum, and CD30+ reactions to parapoxvirus are discussed...
  91. ncbi HLA-G and IL-10 expression in human cancer--different stories with the same message
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, Switzerland
    Semin Cancer Biol 13:337-42. 2003
    ..This article reviews the current literature on this topic and provides new insights into the role of HLA-G and IL-10 in cancer...
  92. ncbi Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations
    Ralf Geertsen
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Int J Cancer 99:82-7. 2002
    ..We could document the occurrence of selective HLA-A2 deficiencies in cultured advanced-stage melanoma metastases and identify their molecular causes as genomic alterations within the HLA-A gene locus...
  93. ncbi Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 104:1631-8. 2004
    ..We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated...
  94. ncbi Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma
    Martin Kleinhans
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Blood 101:1487-93. 2003
    ..These results suggest that expression of CCR3 and its ligand eotaxin/CCL11 plays a role in the recruitment and retention of CD30(+) malignant T cells to the skin...
  95. ncbi Hepatitis C and G viruses in B-cell lymphomas of the skin
    Sonja Michaelis
    Unit of Dermatopathology, Department of Dermatology, University Hospital, Zurich, Switzerland
    J Cutan Pathol 30:369-72. 2003
    ..Most studies were performed in patients with known HCV infection, but the overall frequency of HCV- and HGV-RNA in tumoral tissue of primary cutaneous B-cell lymphomas (CBCLs) is unknown...
  96. ncbi Successful imiquimod treatment of multiple basal cell carcinomas after radiation therapy for Hodgkin's disease
    Mirjam Beyeler
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich Switzerland
    Eur J Dermatol 15:52-5. 2005
    ..Until now he is in complete remission. However, multiple superficial basal cell carcinomas have developed on irradiation fields that have been successfully treated by imiquimod...
  97. ncbi Granulomatous slack skin responds to UVA1 phototherapy
    Patrick A Oberholzer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 219:268-71. 2009
    ..A follow-up 12 months after phototherapy showed continued treatment benefit. To our knowledge, this is the first report describing the successful use of UVA1 (340-400 nm) phototherapy in a patient with GSS...
  98. ncbi Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 15:392-400. 2006
    ....
  99. ncbi Emerging drugs in cutaneous T-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Expert Opin Emerg Drugs 10:381-92. 2005
    ....
  100. ncbi UV protection and skin cancer
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Recent Results Cancer Res 160:7-12. 2002
    ..We conclude that there is substantial evidence that UV protection is able to reduce the risk of actinic keratosis, squamous cell carcinoma and probably also the risk of melanoma...
  101. ncbi Small bowel invagination caused by intestinal melanoma metastasis: unsuspected diagnosis by FDG-PET/CT imaging
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Clin Nucl Med 32:213-4. 2007